Hybio Pharmaceutical (300199) Stock Overview
Engages in the research, development, production, and marketing of peptide and oligonucleotide drugs in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
300199 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Hybio Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥21.04 |
| 52 Week High | CN¥31.19 |
| 52 Week Low | CN¥16.23 |
| Beta | 0.72 |
| 1 Month Change | -5.57% |
| 3 Month Change | -3.22% |
| 1 Year Change | 12.57% |
| 3 Year Change | 107.29% |
| 5 Year Change | 310.94% |
| Change since IPO | 10.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| 300199 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -14.0% | -4.2% | -4.7% |
| 1Y | 12.6% | -11.6% | 10.6% |
Return vs Industry: 300199 exceeded the CN Pharmaceuticals industry which returned -11.6% over the past year.
Return vs Market: 300199 exceeded the CN Market which returned 10.6% over the past year.
Price Volatility
| 300199 volatility | |
|---|---|
| 300199 Average Weekly Movement | 10.5% |
| Pharmaceuticals Industry Average Movement | 6.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in CN Market | 12.3% |
| 10% least volatile stocks in CN Market | 4.3% |
Stable Share Price: 300199's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 300199's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 1,226 | Yu Pinxiang | www.hybio.com.cn |
Hybio Pharmaceutical Co., Ltd. engages in the research, development, production, and marketing of peptide and oligonucleotide drugs in China and internationally. The company offers finished dosage form (FDF) products for obstetrics and gynecology, haemostatic agent, digestive tract and metabolic systems, immune system modulation, cardiovascular, diabetes mellitus, and osteoporosis, as well as disposable injectable pens; and peptide active pharmaceutical ingredients (API) comprising polypeptides, small molecules and nucleic acids, and intermediates for endocrine, nutritional, and metabolic diseases; digestive system diseases; neoplasms; nervous system diseases; pregnancy, childbirth, and puerperium; musculoskeletal system and connective tissue diseases; infectious and parasitic diseases; circulatory system diseases; blood and hematopoietic organ diseases; and genitourinary system diseases, as well as factors influencing health status. It also provides contract research, development, and manufacturing organization (CRDMO) services for peptide APIs, peptide formulations, oligonucleotide drugs, and pharmaceutical intermediates.
Hybio Pharmaceutical Co., Ltd. Fundamentals Summary
| 300199 fundamental statistics | |
|---|---|
| Market cap | CN¥18.58b |
| Earnings (TTM) | CN¥94.52m |
| Revenue (TTM) | CN¥955.53m |
Is 300199 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300199 income statement (TTM) | |
|---|---|
| Revenue | CN¥955.53m |
| Cost of Revenue | CN¥404.16m |
| Gross Profit | CN¥551.37m |
| Other Expenses | CN¥456.85m |
| Earnings | CN¥94.52m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 21, 2026
| Earnings per share (EPS) | 0.11 |
| Gross Margin | 57.70% |
| Net Profit Margin | 9.89% |
| Debt/Equity Ratio | 258.8% |
How did 300199 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/23 00:29 |
| End of Day Share Price | 2026/07/23 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hybio Pharmaceutical Co., Ltd. is covered by 11 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yalei Yan | Bohai Securities Co., Ltd. |
| Jin Zhang | China International Capital Corporation Limited |
| You You Liu | China Stock Investment Research Co. Ltd. (DeepValue.online) |